Abstract Library

#4186 The effect of the Covid-19 pandemic on the body composition of patients with gastroenteropancreatic neuroendocrine tumors using a somatostatin analogue

Introduction: The Covid-19 pandemic and its restrictions had a negative impact on the general population. Due to lockdowns, food intake increased and exercise decreased. This led to weight gain and changes in body composition. Hospitals reviewed patients (pts) remotely. The effect of the Covid-19 pandemic has not been described in pts with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with somatostatin analogue (SSA).

Conference:

Presenting Author: Clement D

Authors: Clement D, Brown S, Dolly S, Mestre-Alagarda C, Giovos G,

Keywords: GEP-NET, SSA, malnutrition, Covid-19 pandemic,

#4181 High prevalence of deficiencies in fat-soluble vitamins, minerals and trace elements but no relation with malnutrition in patients with gastroenteropancreatic neuroendocrine tumors using somatostatin analogues

Introduction: Since 2019 the Global Leadership Into Malnutrition (GLIM) criteria exist for diagnosing malnutrition. Patients (pts) with gastoenteropancreatic (GEP) neuroendocrine tumors (NETs) treated with somatostatin analogues (SSAs) are at risk of malnutrition. Deficiencies in fat-soluble vitamins, minerals and trace elements (micronutrients) are not part of the GLIM criteria but frequently reported in pts with GEP-NETs treated with SSAs.

Conference:

Presenting Author: Clement D

Authors: Clement D, van Leerdam M, Tesselaar M, Cananea E, Martin W,

Keywords: gastroenteropancreatic neuroendocrine tumor, somatostatin analogue, malnutrition, sarcopenia, survival,

#4173 The global leadership into malnutrition criteria reveals a high percentage of malnutrition which negatively influences overall survival in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with somatostatin analogues

Introduction: Patients (pts) with GEP-NETs treated with somatostatin analogues (SSA’s) are at risk of malnutrition. This has been reported, using weight loss or body mass index (BMI) only. The Global leadership into malnutrition (GLIM) criteria include weight loss, BMI and sarcopenia. In pts with other types of cancer the presence of malnutrition, has a negative effect on overall survival (OS). In pts with GEP-NETs treated with SSA’s this has not been explored before.

Conference:

Presenting Author: Clement D

Authors: Clement D, van Leerdam M, Tesselaar M, Cananea E, Martin W,

Keywords: gastroenteropancreatic neuroendocrine tumor, somatostatin analogue, malnutrition, sarcopenia, survival,

#3941 Association of body composition with survival in patients with Pancreatic Neuroendocrine Tumors (PNET) following curative resection

Introduction: The body composition has been demonstrated to be associated with the prognosis of various cancers. However, the prognostic value of body composition in patients with pancreatic neuroendocrine tumors (pNETs) following curative resection is still unknown.

Conference:

Presenting Author: Xie Z

Authors: Shen X, Wang Z, Liu X, Wang X, Xie Z,

Keywords: body composition, pNETs, computed tomography, survival,

#3849 Is patient's BMI representative of their body composition in neuroendocrine tumors?

Introduction: Up to 60% of patients with neuroendocrine tumors (NETs) are malnourished. This negatively impacts survival, length of hospital stay, risk of complications, treatment response, fatigue and quality of life. Malnutrition is typically defined by body mass index (BMI) or weight loss, which provides no information on body composition. Research in other cancers has shown sarcopenia is more significant than BMI. Information is lacking on the influence of anthropometric parameters in NETs.

Conference:

Presenting Author: Bradley E

Authors: Bradley E, Shah T,

Keywords: neuroendocrine, body composition, handgrip strength, mid arm muscle circumference,